Search Results - "Conlon, Tj"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study by Corti, M, Elder, Me, Falk, Dj, Lawson, L, Smith, Bk, Nayak, S, Conlon, Tj, Clément, N, Erger, K, Lavassani, E, Green, M, Doerfler, Pa, Herzog, Rw, Byrne, Bj

    “…Gene therapy strategies for congenital myopathies may require repeat administration of adeno-associated viral (AAV) vectors in response to several limitations…”
    Get full text
    Journal Article
  2. 2

    Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs by Boyd, R F, Boye, S L, Conlon, T J, Erger, K E, Sledge, D G, Langohr, I M, Hauswirth, W W, Komáromy, A M, Boye, S E, Petersen-Jones, S M, Bartoe, J T

    Published in Gene therapy (01-06-2016)
    “…Adeno-associated virus (AAV) vector-based gene therapy is a promising treatment strategy for delivery of neurotrophic transgenes to retinal ganglion cells…”
    Get full text
    Journal Article
  3. 3

    Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver by LOILER, S. A, CONLON, T. J, MUZYCZKA, N, FLOTTE, T. R, SONG, S, TANG, Q, WARRINGTON, K. H, AGARWAL, A, KAPTURCZAK, M, LI, C, RICORDI, C, ATKINSON, M. A

    Published in Gene therapy (01-09-2003)
    “…Human pancreatic islet cells and hepatocytes represent the two most likely target cells for genetic therapy of type I diabetes. However, limits to the…”
    Get full text
    Journal Article
  4. 4

    Recombinant adeno-associated virus vectors for gene therapy by Conlon, Thomas J, Flotte, Terence R

    Published in Expert opinion on biological therapy (01-07-2004)
    “…Recombinant adeno-associated virus (rAAV) vectors are based on a non-pathogenic human parvovirus (AAV) that is unique in its ability to persist in human cells…”
    Get more information
    Journal Article
  5. 5
  6. 6

    Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector by Conlon, Thomas J, Walter, Glenn, Owen, Renius, Cossette, Travis, Erger, Kirsten, Gutierrez, Greg, Goetzman, Eric, Matern, Dietrich, Vockley, Jerry, Flotte, Terence R

    Published in Human gene therapy (01-01-2006)
    “…Mitochondrial beta-oxidation of fatty acids is required to meet physiologic energy requirements during illness and periods of fasting or physiologic stress,…”
    Get more information
    Journal Article
  7. 7

    Gene Therapy for Pyruvate Dehydrogenase E1α Deficiency Using Recombinant Adeno-Associated Virus 2 (rAAV2) Vectors by Owen, Renius, Mandel, Ronald J., Ammini, Chandramohan V., Conlon, Thomas J., Kerr, Douglas S., Stacpoole, Peter W., Flotte, Terence R.

    Published in Molecular therapy (01-09-2002)
    “…To determine the feasibility of gene transfer to correct defects in the E1α subunit of the pyruvate dehydrogenase (PDH) complex (PDC), we constructed rAAV…”
    Get full text
    Journal Article
  8. 8

    Evaluation of a fertilized 3-pasture system grazed by yearling steers [North Dakota] by Nyren, Paul E., Whitman, Warren C., Nelson, James L., Conlon, Thomas J.

    Published in Journal of range management (01-05-1983)
    “…A grazing trial comparing fertilized and unfertilized 3-pasture systems has shown that the addition of 56 kg nitrogen (N)/ha substantially improved forage and…”
    Get full text
    Journal Article